Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy
Abstract Reactivation of Human Endogenous Retrovirus K (HERV-K), subtype HML-2, has
been associated with pathophysiology of amyotrophic lateral sclerosis (ALS). We aimed to
assess the efficacy of antiretroviral therapy in inhibiting HML-2 in patients with ALS and a
possible association between the change in HML-2 levels and clinical outcomes. We
studied the effect of 24-weeks antiretroviral combination therapy with abacavir, lamivudine,
and dolutegravir on HML-2 levels in 29 ALS patients. HML-2 levels decreased progressively …
been associated with pathophysiology of amyotrophic lateral sclerosis (ALS). We aimed to
assess the efficacy of antiretroviral therapy in inhibiting HML-2 in patients with ALS and a
possible association between the change in HML-2 levels and clinical outcomes. We
studied the effect of 24-weeks antiretroviral combination therapy with abacavir, lamivudine,
and dolutegravir on HML-2 levels in 29 ALS patients. HML-2 levels decreased progressively …